Guided Therapeutics annual gross margin
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
Guided Therapeutics's gross margin was 74.45% for fiscal 2025.
View full Guided Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 74.45% | +45.87 pp |
| 2024 | 2024-12-31 | 28.57% | −8.16 pp |
| 2023 | 2023-12-31 | 36.73% | +559.81 pp |
| 2022 | 2022-12-31 | −523.08% | −547.77 pp |
| 2021 | 2021-12-31 | 24.69% | −115.50 pp |
| 2020 | 2020-12-31 | 140.20% | +234.64 pp |
| 2019 | 2019-12-31 | −94.44% | −38.30 pp |
| 2018 | 2018-12-31 | −56.14% | +61.07 pp |
| 2017 | 2017-12-31 | −117.21% | −181.50 pp |
| 2015 | 2015-12-31 | 64.29% | +268.90 pp |
| 2014 | 2014-12-31 | −204.62% | −173.88 pp |
| 2013 | 2013-12-31 | −30.73% | −29.38 pp |
| 2012 | 2012-12-31 | −1.35% | +0.90 pp |
| 2011 | 2011-12-31 | −2.25% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | 77.46% | +10.79 pp |
| Q3 2025 | 2025-09-30 | 58.33% | +8.33 pp |
| Q2 2025 | 2025-06-30 | 67.52% | +42.52 pp |
| Q4 2024 | 2024-12-31 | −200.00% | −259.09 pp |
| Q1 2024 | 2024-03-31 | 66.67% | −33.33 pp |
| Q4 2023 | 2023-12-31 | 50.00% | −30.00 pp |
| Q2 2023 | 2023-06-30 | 25.00% | −55.00 pp |
| Q1 2023 | 2023-03-31 | 59.09% | −9.24 pp |
| Q3 2022 | 2022-09-30 | 100.00% | +221.05 pp |
| Q2 2022 | 2022-06-30 | 80.00% | −20.00 pp |
| Q1 2022 | 2022-03-31 | 80.00% | −256.00 pp |
| Q4 2021 | 2021-12-31 | 68.33% | −16.08 pp |
| Q3 2021 | 2021-09-30 | −121.05% | −196.05 pp |
| Q2 2021 | 2021-06-30 | 100.00% | 0.00 pp |
| Q4 2020 | 2020-12-31 | 336.00% | +6736.00 pp |
| Q3 2020 | 2020-09-30 | 84.42% | −10.03 pp |
| Q4 2019 | 2019-12-31 | 75.00% | +172.67 pp |
| Q3 2019 | 2019-09-30 | 100.00% | 0.00 pp |
| Q2 2019 | 2019-06-30 | −6,400.00% | −6487.50 pp |
| Q1 2019 | 2019-03-31 | 94.44% | +69.44 pp |
| Q4 2018 | 2018-12-31 | −97.67% | +127.57 pp |
| Q3 2018 | 2018-09-30 | 100.00% | +293.94 pp |
| Q2 2018 | 2018-06-30 | 87.50% | +81.75 pp |
| Q1 2018 | 2018-03-31 | 25.00% | +1.19 pp |
| Q4 2017 | 2017-12-31 | −225.24% | −235.77 pp |
| Q3 2017 | 2017-09-30 | −193.94% | −2849.49 pp |
| Q2 2017 | 2017-06-30 | 5.75% | +1605.75 pp |
| Q1 2017 | 2017-03-31 | 23.81% | +1063.81 pp |
| Q3 2016 | 2016-09-30 | 10.53% | −122.81 pp |
| Q4 2015 | 2015-12-31 | 2,655.56% | +2617.09 pp |
| Q3 2015 | 2015-09-30 | −1,600.00% | −1609.09 pp |
| Q2 2015 | 2015-06-30 | −1,040.00% | −403.64 pp |
| Q1 2015 | 2015-03-31 | 133.33% | +501.75 pp |
| Q4 2014 | 2014-12-31 | 38.46% | +86.00 pp |
| Q3 2014 | 2014-09-30 | 9.09% | +77.70 pp |
| Q2 2014 | 2014-06-30 | −636.36% | −635.01 pp |
| Q1 2014 | 2014-03-31 | −368.42% | −352.85 pp |
| Q4 2013 | 2013-12-31 | −47.54% | −45.80 pp |
| Q3 2013 | 2013-09-30 | −68.60% | −63.58 pp |
| Q2 2013 | 2013-06-30 | −1.35% | — |
| Q1 2013 | 2013-03-31 | −15.57% | — |
| Q3 2012 | 2012-09-30 | −1.73% | — |
| Q2 2012 | 2012-06-30 | −5.03% | — |
Over the last five reported fiscal years, Guided Therapeutics's gross margin decreased from 140.20% to 74.45%, a change of −65.75 percentage points. The latest reported quarter, Q4 2025, shows 77.46%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Guided Therapeutics filings at SEC.gov ↗